BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 26, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Nov. 4, 2022

View Archived Issues
Acquisition target

Werfen acquires Immucor for $2B

Private equity firm TPG Inc. validated rumors circulating since August that it was seeking a buyer for Immucor Inc. with the announcement of an agreement to sell the diagnostics company for $2 billion to Werfen SA. Immucor offers transfusion and transplantation diagnostics making it a natural fit for Werfen, which develops specialized diagnostic instruments, reagents and data management solutions. The deal is expected to close in the first half of 2023. Read More

ACC and AHA update aortic disease guidelines

The American College of Cardiology and the American Heart Association (AHA) released new guidelines for the diagnosis and management of aortic disease just ahead of this year’s AHA Scientific Sessions, which start Nov. 5 in Chicago. The update is the first comprehensive revision to the guidelines since 2010. Key recommendations address screening and diagnostic testing, imaging, patient involvement in care decisions and when to consider surgery. Read More
Regulatory-US-FDA-HQ.png

FDA advisory offers mixed endorsement for class III designation for tissue expanders

The U.S. FDA held a two-day advisory hearing in the last week of October 2022 to address some lingering regulatory questions, including the question of whether therapeutic nail prostheses should be a class I device. The potentially more dramatic shift, however, would be the application of a class III risk designation to tissue expanders used in breast surgery. Read More
Intus Care founders

Intus Care raises $14.1M for geriatric care platform

Predictive analytics startup Intus Care Inc. scooped up $14.1 million in a series A round led by Deerfield Management. The funds will be used to advance and scale its software platform for geriatric care. Read More
Brain illustration

‘On-demand’ epilepsy gene therapy selectively calms hyperactive cells

By pairing the expression of an inhibitory ion channel with an activity-dependent promoter, researchers have developed the first on-demand gene therapy that specifically silenced hyperactive cells and prevented epileptic seizures. Read More

BioWorld MedTech Patent Highlights: Week 43

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette. Read More

Financings for Nov. 4, 2022

Med-tech firms raising money in public or private financings, including: Novadip. Read More

Other news to note for Nov. 4, 2022

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: ADI Health, Mast, Nanomix, Vitalhub. Read More

Regulatory actions for Nov. 4, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avita Medical, Neurosteer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 26, 2026.
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • Art concept for Parkinson's disease

    Emerging therapeutic strategies for Parkinson’s at ADPD 2026

    BioWorld
    Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 24, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing